Makbule Şenel1, Samir Abu‐Rumeileh1, Detlef Michel2, Tamara Garibashvili1, Katharina Althaus1, Jan Kassubek1, Markus Otto1
1Department of Neurology, Ulm University Hospital, Ulm, Germany
2Department of Virology, Ulm University Hospital, Ulm, Germany
Tóm tắt
Miller‐Fisher syndrome (MFS) is classified as a variant of Guillain–Barré syndrome (GBS), accounting for 5%–25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS‐CoV‐2 infection test.
